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Summary 
Remifentanil is a commonly used opioid in anesthesia with 
cardioprotective effect in ischemia-reperfused (I/R) heart. We 
evaluated the influence of remifentanil on myocardial infarct size 
and expressions of proteins involved in apoptosis in I/R rat heart 
following various time protocols of remifentanil administration. 
Artificially ventilated anesthetized Sprague-Dawley rats were 
subjected to a 30 min of left anterior descending coronary artery 
occlusion followed by 2 h of reperfusion. Rats were randomly 
assigned to one of five groups; Sham, I/R only, remifentanil 
preconditioning, postconditioning and continuous infusion group. 
Myocardial infarct size, the phosphorylation of ERK1/2, Bcl2, Bax 
and cytochrome c and the expression of genes influencing Ca2+ 
homeostasis were assessed. In remifentanil-administered rat 
hearts, regardless of the timing and duration of administration, 
infarct size was consistently reduced compared to I/R only rats. 
Remifentanil improved expression of ERK 1/2 and anti-apoptotic 
protein Bcl2, and expression of sarcoplasmic reticulum genes 
which were significantly reduced in the I/R rats only. 
Remifentanil reduced expression of pro-apoptotic protein, Bax 
and cytochrome c. These suggested that remifentanil produced 
cardioprotective effect by preserving the expression of proteins 
involved in anti-apoptotic pathways, and the expression of 
sarcoplasmic reticulum genes in I/R rat heart, regardless of the 
timing of administration. 
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Introduction 
 
 Despite restoration of coronary blood flow, 
ischemia-reperfusion (I/R) injury in myocardium triggers 
stress signaling processes that eventually result in various 
degree of myocardial damage (Anaya-Prado et al. 2002, 
Fliss and Gattinger 1996). In attempts to lessen the I/R 
injury, ischemic preconditioning was introduced as an 
effective treatment modality (Murry et al. 1986). Certain 
anesthetic agents also possess cardioprotective effects 
against I/R injury, mimicking ischemic preconditioning, 
termed pharmacological preconditioning (Schultz and 
Gross 2001, Tanaka et al. 2004). Remifentanil, is an 
ultra-short-acting, selective, µ-opioid receptor agonist, 
gaining increasing popularity in cardiac anesthesia (Glass 
1995, Patel and Spencer 1996). Like several anesthetics, 
remifentanil was reported to protect myocardium against 
I/R injury. In the light of remifentanil’s preconditioning 
effect, the activation of opioid receptors (Peart et al. 
2005, Yu et al. 2007, Zhang et al. 2004), protein kinase C 
(PKC) and mitochondrial adenosine triphosphate-
sensitive potassium (KATP) channels were reported to be 
important mediators of its cardioprotective action (Zhang 
et al. 2005), although those were observed at doses much 
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higher than doses used in clinical practice. 
 Apoptosis, a programmed cell death, contributes 
significantly to post-ischemic cardiomyocyte death, 
(Gottlieb and Engler 1999) but evidence is lacking 
regarding the effect of remifentanil on anti-apoptotic 
pathways of survival in I/R injury. In mammalian cells, 
among three major mitogen-activated protein kinases 
(MAPKs) signaling pathways, activation of extracellular 
signal related protein kinases (ERK1/2) exerts beneficial 
effect on post-ischemic myocardial apoptosis (Yue et al. 
2000).  
 Thus, we evaluated the effects of the minimal 
concentration of remifentanil (Yu et al. 2007, Zhang et 
al. 2005) against I/R injury on myocardial infarction in 
rat in terms of the expression of proteins involved in 
apoptosis signaling cascades including ERK1/2 following 
various time protocols of remifentanil administration in 
rat heart. In addition, since the proteins involved in 
apoptosis significantly affect Ca2+ homeostasis, we 
concomitantly measured expressions of genes associated 
with Ca2+ homeostasis. 
 
Methods 
 
Animals 
 Male Sprague-Dawley rats (250-300 g) were 
anesthetized with a single i.p. injection of pentobarbital 
60 mg/kg (Yu et al. 2007, Zhang et al. 2004). Anesthesia 
was maintained by repeated doses of pentobarbital 25 mg 
kg-1 every 60-90 min. After tracheal intubation, the rats 
were artificially ventilated (Harvard Apparatus 683, 
USA) at a rate of 30-35 cycles per minute with oxygen 
100 % and a tidal volume of approximately 5 ml. The 
respiratory rate was varied to maintain the end-tidal CO2 
by 30-35 mm Hg using a capnograph (Datec, 
Normocap®, Finland). 
 The right femoral artery was used for monitoring 
of mean arterial pressure, and the heart rate was 
monitored via subcutaneous stainless steel electrodes. 
These were connected to a PowerLab monitoring system 
(ML845 PowerLab with ML132; AD Instruments, USA). 
The left femoral vein was cannulated to infuse 
remifentanil or saline. Rectal temperature was maintained 
at 38 °C during the entire experiment. The animal 
experimental procedures were approved by the committee 
for the Care and Use of Laboratory Animals of our 
hospital and were performed in accordance with the 
Committee’s Guidelines and Regulations for Animal 
Care. 
Experimental protocol 
 After a left thoracotomy and pericardiotomy, the 
heart was exposed and a suture was passed around the left 
anterior descending (LAD) coronary artery by inserting a 
small curved Prolene 6.0 needle into the margin of the 
pulmonary cone, exiting through the middle of a line 
linking the cone to the atrium. The suture ends were 
threaded through a small vinyl tube to prepare a snare. 
After surgical preparation, the rat was allowed to stabilize 
for 20 min. In all groups, the LAD coronary artery was 
occluded for 30 min by tightening the snare. Myocardial 
ischemia was confirmed by the appearance of a regional 
cyanosis on the epicardium distal to the snare and 
akinesia or bulging in this area. After 30 min of ischemia, 
the snare was released and reperfusion allowed for a 
period of 2 h. Hemodynamic parameters were measured 
at following time points; 1) at the end of stabilization 
before ischemia (baseline), 2) at the end of ischemia (or 
no ischemia), and 3) after 2 h of reperfusion (Fig. 1). 
 
Study groups 
 This study consisted of five series of 
experiments. ‘I/R’: rats did not receive any remifentanil 
(UltivaTM, GlaxoSminthKline, Italy) treatment during the 
entire experiment (n=7); ‘Remifentanil-preconditioning 
(Pre-R)’: rats were subjected to infusion of remifentanil 
(6 μg kg-1min-1) during 20 min before 30 min of 
occlusion followed by 10 min washout (n=6); 
‘Remifentanil-postconditioning (Post-R)’: remifentanil 
was administered during the first 20 min of reperfusion 
(n=7); ‘Long-R’: remifentanil was administered from 
30 min before ischemia to the first 20 min of reperfusion 
(n=9). Control sham-operated rats (Sham) were treated 
similarly, except that the coronary suture was not tied, 
and remifentanil was not administered (n=5). 
 
Infarct size measurement 
 At the end of the reperfusion period (2 h), the 
heart was excised and immersed in 2 % triphenyl-
tetrazolium chloride (TTC) (Sigma, USA) stain for 
20 min at 37 °C. The infarct myocardium, which does not 
take up TTC stain when the dehydrogenase enzymes are 
drained off, remains pale in color. The heart was sliced 
and photographed, and infarct size was determined by 
dividing the total necrotic area of the left ventricle (LV) 
by the total LV area (Kang et al. 2006, Hwang et al. 
2004, Gnecchi et al. 2006). The boundary of unstained 
area was traced in a blinded fashion and quantified with 
NIH image, version 1.61. 
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Fig. 1. The experimental protocol. Occlusion of the left anterior (LAD) coronary artery was maintained for 30 min, followed by 
reperfusion. After 2 h, sampling was performed for infarct size, immunoblot and RT-PCR, respectively. Sham, the coronary suture was 
not tied, and remifentanil was not administered; I/R, ischemia/reperfusion group (n=7); Pre-R, remifentanil administered during the 
preconditioning period (n=6); Post-R, remifentanil administered during the first 20 min of reperfusion (n=7); Long-R, remifentanil 
administered during the entire period (from the preconditioning to the first 20 min of reperfusion) (n=9). 
 
 
Immunoblot analysis 
 At the end of the reperfusion period, tissue 
preparation was performed (Uecker et al. 2003). Briefly, 
LV specimens were pulverized and dissolved in lysis 
buffer (Cell signaling, USA). The solution was 
vigorously homogenized with Pyrex Potter-Elvehjem 
Tissue Grinders (BLD science, USA) and then 
centrifuged at 12,000 x g for 10 min at 4 °C, and 
supernatant was transferred to a new tube and stored at  
–70 °C. Protein concentrations were determined using the 
Bradford protein assay kit (BioRad, USA). Proteins were 
separated in a 12 % SDS-polyacrylamide gel and 
transferred to PVDF membrane (Millipore Co, USA). 
After blocking the membrane with Tris-buffered saline-
Tween 20 (TBS-T, 0.1 % Tween 20) containing 5 % non-
fat dried milk for 1 h at room temperature, membranes 
were washed twice with TBS-T and incubated with 
primary antibodies for 1 h at room temperature or for 
overnight at 4 °C. The following primary antibodies were 
used: rabbit anti- extracellular signal-regulated kinases 
(ERK 1/2), mouse anti-phospho ERK 1/2, mouse anti-
B cell leukemia/lymphoma-2 (Bcl-2), mouse anti-
cytochrome C (Santa Cruz Biotechnology, USA), rabbit 
anti-Bcl-2-associated X protein (Bax) (Assay Designs, 
USA) and mouse anti-β actin antibodies (Sigma, USA). 
The membranes were washed three times with TBS-T for 
10 min, and then incubated for 1 h at room temperature 
with horseradish peroxidase (HRP)-conjugated secondary 
antibodies. After extensive washing, the bands were 
detected by enhanced chemiluminescence (ECL) reagent 
(Santa Cruz Biotechnology, USA). β-actin gene was used 
as the standards for equal of the protein samples. The 
band intensities were quantified using a Photo-Image 
System (Molecular Dynamics, Sweden). Each experiment 
was performed at least three times. 
 
RT-PCR analysis 
 At the end of the reperfusion period, tissue 
preparation was performed (Uecker et al. 2003). Briefly, 
LV samples were vigorously homogenized with Pyrex 
Potter-Elvehjem Tissue Grinders (BLD science, USA) in 
TRI Reagent (Sigma, USA). Total RNA was prepared by 
the UltraspectTM-II RNA system (Biotecx Laboratories, 
Inc., USA) and single-stranded cDNA was then 
synthesized from isolated total RNA by Avian 
Myeloblastosis virus (AMV) reverse transcriptase. A 
20 µl reverse transcription reaction mixture containing 
1 µg of total RNA, 1X reverse transcription buffer 
(10 mM Tris-HCl, pH 9.0, 50 mM KCl, 0.1 % Triton X-
100), 1 mM deoxynucleoside triphosphates (dNTPs), 
0.5 unit of RNase inhibitor, 0.5 µg of oligo (dT)15 and 
15 units of AMV reverse transcriptase were incubated at 
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42 °C for 15 min, heated to 99 °C for 5 min, and then 
incubated at 0-5 °C for 5 min. All primer pairs for DNA 
sequencing of genes related to Ca2+ homeostasis are 
shown in Table 1. The PCR condition was 94 °C for 
3 min, 94 °C for 1 min, 41-49 °C for 1 min and 72 °C for 
2 min, 35 cycles, with a final extension for 10 min at 
72 °C. GAPDH gene (primers 5'-accacagtccatgccatcac-3' 
and 5'-tccaccaccctgttgctgta-3', 450 bp) was used as the 
internal standard. The signal intensity of the amplification 
product was analyzed using the UVlband software 
(UVltec, UK). 
 
Statistical analysis 
 Data are presented as means ± SD or means ± 
SEM. Where results of blots and RT-PCR are shown, a 
representative experiment is depicted. Data analysis was 
performed with statistical software program Prism v3.0 
(GraphPad Software, USA). Hemodynamics was 
analyzed using two-way analysis of variance (ANOVA) 
with Bonferroni post-hoc test for multiple comparisons if 
F ratio was significant. Infarct sizes were analyzed 
between groups using ANOVA with Student-Newman-
Keula post-hoc test for multiple comparisons. Statistical 
significance was defined as P<0.05 and P<0.01. 
 
Results 
 
Hemodynamics 
 The heart rate and mean arterial pressure are 
summarized in Table 2. The heart rates in the Post-R 
(P<0.05) and Long-R groups (P<0.01) were significantly 
lower compared to the I/R group after reperfusion. The 
Table 1. The nucleotide sequence of all primer pairs for proteins related to Ca2+ homeostasis. 
 
Genes Primer sequence Size (bp) 
L-type Ca2+-channel Sense: 5′-TGTCACGGTTGGGTAGTGAA-3′ 
Antisense: 5′-TTGAGGTGGAAGGGACTTTG-3′ 
346 
PMCA1 Sense: 5′-TGCCTTGTTGGGATTTCTCT-3′ 
Antisense: 5′-CACTCTGGTTCTGGCTCTCC-3′ 
351 
NCX Sense: 5′-TGTCTGCGATTGCTTGTCTC-3′ 
Antisense: 5′-TCACTCATCTCCACCAGACG-3′ 
364 
SERCA2a Sense: 5′-TCCATCTGCCTGTCCAT-3′ 
Antisense: 5′-GCGGTTACTCCAGTATTG-3′ 
196 
Phospholamban Sense: 5′-GCTGAGCTCCCAGACTTCAC-3′ 
Antisense: 5′-GCGACAGCTTGTCACAGAAG-3′ 
339 
Ryanodine receptor 2 Sense: 5′-CCAACATGCCAGACCCTACT-3′ 
Antisense: 5′-TTTCTCCATCCTCTCCCTCA-3′ 
351 
Calsequestrin Sense: 5′-TCAAAGACCCACCCTACGTC-3′ 
Antisense: 5′-CCAGTCTTCCAGCTCCTCAG-3′ 
352 
 
 
Table 2. Hemodynamic parameters. 
 
Baseline Ischemia 2 h after reperfusion 
 HR MAP HR MAP HR MAP 
I/R 437 ± 52 131 ± 14 446 ± 67 127 ± 17 449 ± 35 129 ± 15 
Pre-R 456 ± 47 144 ± 7 467 ± 57 129 ± 8 462 ± 48 134 ± 10 
Post-R 397 ± 61 129 ± 10 402 ± 48 132 ± 9 347 ± 48 * 118 ± 15 
Long-R 424 ± 38 135 ± 11 384 ± 41 101 ± 6 ∗‡ 345 ± 40 ** † 99 ± 25 † 
 
HR, heart rate; MAP, mean arterial pressure; I/R, ischemia/reperfusion group (n=7); Pre-R, remifentanil administered during the 
preconditioning period (n=6); Post-R, remifentanil administered during the first 20 min of reperfusion (n=7); Long-R, remifentanil 
administered during the entire period (from the preconditioning to the first 20 min of reperfusion) (n=9). Data are mean ± SD. 
∗ P<0.05, ∗ ∗ P<0.01 vs. I/R group; † P<0.05, ‡ P<0.01 vs. baseline. 
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heart rate in the Long-R groups after reperfusion was also 
significantly lower compared to the baseline value 
(P<0.05). The mean arterial pressures significantly 
decreased at the end of ischemia (P<0.01) and after 
reperfusion (P<0.05) compared to the baseline value in 
the Long-R groups. The other values of heart rate and 
mean arterial pressure revealed no significant differences 
in either inter- or intra-group comparisons. 
 
Infarct size measurement 
 Mean infarct size of the LV in the I/R group was 
43.6 (5.5) %. In the groups administered with 
remifentanil, infarct sizes of the LV were significantly 
reduced to 20.1 (1.9) %, 18.8 (3.8) % and 19.3 (3.2) % in 
the Pre-R, Post-R and Long-R group, respectively (all 
P<0.05). No significant differences were observed 
between the remifentanil-administered groups (Fig. 2). 
 
Western blotting analysis on phosphorylation of ERK 1/2 
and apoptosis related proteins 
 Phosphorylations of ERK 1/2 were significantly 
lower in the I/R group than in the Sham group. 
Phosphorylations of ERK 1/2 in the remifentanil-
administered groups were significantly improved 
compared to the I/R group, but were lower than in the 
Sham group. Phosphorylations of ERK 1/2 were similar 
between the remifentanil-administered groups (Fig. 3A). 
 Expression levels of pro-apoptotic proteins, Bax 
and cytochrome c, significantly increased and expression 
level of anti-apoptotic protein, Bcl-2 significantly 
decreased in the I/R group than in the Sham group. In the 
remifentanil-administered groups, the expression levels 
of Bax and cytochrome c significantly decreased and the 
expression level of Bcl-2 significantly increased than in 
the I/R group. The expression levels of Bax, cytochrome 
c and Bcl-2 were similar among the remifentanil-
administered groups (Fig. 3B). 
 
Gene expression of proteins influencing the calcium 
homeostasis  
 In the I/R group, gene expression for 
sarcoplasmic reticulum (SR) proteins including SR Ca2+-
ATPase (SERCA2a), phospholamban (PLB), ryanodine 
receptor 2 (RyR), and calsequestrin (CSQ) was reduced 
compared to Sham group. In remifentanil-administered 
groups, mRNA transcription levels for SR proteins were 
significantly up-regulated than in the I/R group without 
differences between the groups. The Ca2+ entry across the 
membrane through L-type Ca2+ channels is balanced by the 
efflux of Ca2+ from the cell via the Na+-Ca2+ exchanger 
(NCX) (Bers 2002). In the present results, levels of gene 
expression for L-type Ca2+ channels and NCX were 
unaltered by I/R with or without remifentanil (Fig. 4). 
 
Discussion 
 
 In the current study, remifentanil significantly 
reduced myocardial infarct size irrespective of the timing 
and duration of administration in I/R rat heart, which 
occurred in conjunction with the preserved 
phosphorylations of ERK 1/2 and anti-apoptotic protein 
Bcl2 and attenuated increased pro-apoptotic proteins, Bax 
and cytochrome c resulting from I/R. Remifentanil 
administration also resulted in preserved gene 
expressions of SR proteins. 
 Remifentanil is a fentanyl derivative with a 
unique pharmacokinetic profile of rapid and predictable 
recovery, gaining increasing popularity in cardiac 
anesthesia. Similar to certain anesthetic agent, 
remifentanil has also been found to possess 
cardioprotective effects against I/R, although the effect 
occurred at significantly higher dose than that clinically 
used (Minto et al. 1997, Scott and Perry 2005). 
Remifentanil was reported to exert cardioprotective effect 
via all three opioid receptors (Peart and Gross 2004, Yu 
et al. 2007). Activation of κ- and δ- opioid receptors was 
associated with activation of PKC and opening of 
mitochondrial KATP channel, which are important targets 
of cardioprotection in ischemic and pharmacological 
preconditioning (Zhang et al. 2005).  
 
Fig. 2. Infarct sizes of the left ventricle in each group. Infarct 
size was expressed as a ratio of the left ventricular area. Values 
are presented as mean ± SEM. * P<0.05 compared with the I/R 
group (n=5-9 per group). 
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 While other signal transduction pathways also 
play an important role in cardioprotection, however, little 
has been studied regarding mechanisms of remifentanil 
induced cardioprotection and we could observe that 
remifentanil acted through proteins involved in anti-
apoptoic pathways of survival regardless of timing and 
duration of administration. Apoptosis has been linked 
with reperfusion-induced myocardial injury after 
reversible coronary occlusion and suggested as one of the 
key mechanisms in the development of infraction in rat 
cardiac myocytes (Buja and Entman 1998, Haunstetter 
and Izumo 2000). 
 
 
 
Fig. 3. Western blot analysis of (A) Western blot analysis of ERK 1/2 and p-ERK 1/2. (B) Western blot analysis of Bcl-2, Bax, and 
cytochrome c. Each signal was quantified by scanning densitometry. Values are presented as mean ± SEM. * P<0.05 and ** P<0.01 
compared with the I/R group.; † P<0.05 and ‡ P<0.01 compared with the Sham group. 
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 In the current study, remifentanil increased the 
phosphorylation of ERK 1/2 and anti-apoptotic proteins 
in I/R rat heart. ERK is activated in response to I/R, 
oxidative stress, and hypoxia, and is an established player 
in the anti-apoptotic defense network (Yue et al. 2000). 
As our results indicate, remifentanil preserved the 
phosphorylation of ERK 1/2 which were significantly 
reduced following I/R leading to improved viability of 
the rat heart exposed to I/R. In response to an apoptotic 
stimulus such as I/R, the pro-apoptotic protein, Bax, 
 
 
 
 
Fig. 4. Analysis of the expressions of genes related to Ca2+ homeostasis. (A) Representative gel image photographs of mRNA levels. 
(B-G) Histograms of SERCA2a (B), phospholamban (C), ryanodine receptor 2 (D), calsequestrin (E), L-type Ca2+-channel (F), and 
NCX (G). GAPDH was used as an internal standard. Each value is the mean ± SEM of 5 hearts/group. * P<0.05 and ** P <0.01 
compared with the I/R group; † P<0.05 and ‡ P<0.01 compared with the Sham group. 
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undergoes a conformational change that allows its 
translocation to the mitochondria, where it induces 
cytochrome c release. Phosphorylation of ERK 1/2 
inhibits the conformational change in Bax protein and 
cytochrome c-induced caspase activation, thereby 
preventing apoptosis (Tsuruta et al. 2004). The anti-
apoptotic protein Bcl-2 attenuates cellular injury by 
inhibiting cytochrome c translocation (Kluck et al. 1997) 
and inhibits Bax translocation (Zhu et al. 2001). During 
ischemic preconditioning, an increase in Bcl-2 in 
association with a decrease in the pro-apoptotic protein 
Bax occurred in isolated rat heart (Lazou et al. 2006). In 
this study, we could observe that improved 
phosphorylations of ERK1/2, and associated recovery of 
expression of Bcl-2 and mitigated expression of Bax and 
mitochondrial cytochrome c release against I/R induced 
injury, which all indicate remifentanil induced a 
cardioprotective effect via anti-apoptosis pathways of 
survival in I/R rat heart.  
 Ca2+ is an important messenger in intracellular 
signal transduction and the balance between Bcl-2 and 
Bax has been demonstrated to affect mitochondrial Ca2+ 
homeostasis, which is important in determining whether 
cells survive or undergo apoptosis. The SR plays a central 
role in regulating the intracellular Ca2+ concentration and 
contains SR Ca2+-cycling proteins such as RyR, 
SERCA2a, PLB, and CSQ. The expression of SR genes 
was significantly reduced in I/R rat heart in this study. 
This was in accordance with the result of previous study 
(Temsah et al. 1999), and treatment with remifentanil 
preserved the levels of SR genes expression. These 
results suggest that remifentanil might modulate the 
expression of SR genes in I/R rat heart. Since we did not 
measure intracellular Ca2+ concentration, the real changes 
in intracellular Ca2+ concentration as consequences of 
remifentanil-induced modulation of Ca2+ homeostasis 
could not be clarified in this study. 
 With regard to the effect of timing and duration 
of drug administration on the extent of myocardial 
protection, the combination of pre- and postconditioning 
with sevoflurane provided additive cardioprotection 
(Obal et al. 2005), whereas desflurane showed no 
additive cardioprotective effects (Haelewyn et al. 2004). 
As we had investigated the cardioprotective effects of 
remifentanil with different administration protocols, we 
observed similar protective effect between remifentanil 
preconditioning and postconditioning groups, and could 
not observe additive cardioprotective effects in 
continuously administered group. These results suggest 
that cardioprotective signaling pathways may vary among 
anesthetics but activated pathways during remifentanil 
pre- and postconditioining might be similar, which merit 
further studies addressing the precise mechanisms of this 
particular anesthetic-induced cardioprotection. 
 Cardioprotective effects of remifentanil in this 
study were demonstrated at a dose of 6 µg kg-1 min-1 
which is higher than the dose used in clinical practice 
(0.2-0.8 µg kg-1 min-1) (Scott and Perry 2005). Previous 
studies reported that remifentanil had cardioprotective 
effect against I/R injury with dose-dependency, and the 
maximum effect of remifentanil was 6 or 10 µg kg-1 min-1 
(Yu et al. 2007, Zhang et al. 2005). Based on those 
studies, we choose the minimal concentration of 
remifentanil inducing maximal cardioprotective effect. 
The pharmacological characteristics of remifentanil may 
vary and it is difficult to compare between species and 
can be given in relatively high doses for a short period of 
time (Yu et al. 2007, Zhang et al. 2005). 
 The limitation of this study is that we did not 
determine the area at risk. In this study, we referred the 
infarct size measurement to the methods of our research 
(Hwang et al. 2004, Kang et al. 2006). Therefore we 
determined the infarct size by dividing the total necrotic 
area by the total LV area. Although this method was used 
in other study (Bazargan et al. 2008), determining the 
necrotic area by the area at risk can be more accurate.  
 In conclusion, remifentanil confers myocardial 
protection against injury in I/R rat heart without reference 
to the timing and duration of administration, which was 
conducted with preserved phosphorylations of ERK 1/2 
and of signal transduction proteins against apoptotic cell 
death, and attenuated changes in expression of SR genes 
related to Ca2+ homeostasis. 
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